13G Filing: Stonepine Capital Management, LLC Details Ownership of Vanda Pharmaceuticals Inc. (VNDA)

Page 1 of 8

We are seeing a lot of 13G filing activity at the moment and one of the more interesting filings is this one submitted to the SEC by Stonepine Capital. This filing details the investor’s latest position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a developer of treatments for unmet medical needs. The pharmaceutical company has thus far brought two products to market, including Fanapt, for the treatment of schizophrenia in adults. The filing includes the amount of shares owned by Stonepine Capital and the total voting power held by the investor (you can see these figures in the table below). Given the investor’s prominent (or once-prominent) position in the stock, we recommend paying close attention to the details in the following filing if you’re considering how to trade the company’s stock right now.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Stonepine Capital, L.P. 2,017,900 0 2,017,90 0 2,017,900 4.7%
Stonepine Capital Management, LLC 2,017,900 0 2,017,90 0 2,017,900 4.7%
Jon M. Plexico 2,017,900 0 2,017,90 0 2,017,900 4.7%
Timothy P. Lynch 2,017,900 0 2,017,90 0 2,017,900 4.7%

Page 1 of 8 SEC Filing

Washington, D.C. 20549


Under the Securities Exchange Act of 1934
(Amendment No. 1)

Vanda Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)


(CUSIP Number)

January 7, 2016**

(Date of Event Which Requires Filing of this

Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:

[] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Potential persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays a currently valid OMB control number.

** The number of shares of the Issuer’s Common Stock (the
“Stock”) reported as beneficially owned herein is the number of shares held or deemed to be beneficially owned by the
Filers (as defined in Item 2) on January 22, 2016. On January 7, 2016, the Filers held or so beneficially owned 2,144,070 shares,
or 5.0% of the outstanding Stock. On December 31, 2015, they held or so beneficially owned 1,918,929 shares, or 4.5% of the outstanding


Follow Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Page 1 of 8